finanzen.net
03.12.2019 17:33
Bewerten
(0)

MCRA Assists CorFlow in Obtaining Breakthrough Device Designation

WASHINGTON, Dec. 3, 2019 /PRNewswire/ -- MCRA, LLC, a leading medical device advisory firm and Clinical Research Organization (CRO) that integrates regulatory, clinical research, reimbursement, compliance and quality assurance, is pleased to announce its role in the successful granting of a Breakthrough Device Designation for the CorFlow Therapeutics AG Controlled Flow Infusion (CoFITM) System by the U.S. Food and Drug Administration (FDA).  The CoFITM System is intended to benefit patients who suffer from microvascular obstruction (MVO) following primary percutaneous coronary intervention (PCI).  This designation enables CorFlow to accelerate the process of bringing the CoFITM System to patients in the US.

MCRA Logo (PRNewsFoto/MCRA)

FDA developed the Breakthrough Designation Program to provide an expedited pathway for novel medical devices that have the potential to provide a treatment option to those suffering from a debilitating or life-threatening condition. Breakthrough Designation provides for increased interaction and timely communication between FDA and device manufacturers during product development and throughout the review process. In addition, the Center for Medicare and Medicaid Services (CMS) has created an alternative new technology add-on payment pathway for devices that have been granted a breakthrough device designation. 

CorFlow retained MCRA in July of 2019 to assist with their US Regulatory Strategy. Jon H. Hoem, CorFlow's CEO and Co-Founder, commented: "Even after receiving a stent, many patients continue to suffer from insufficient perfusion of the heart following a heart attack, resulting in unresolved chest pain and higher risks of heart failure and death.  CorFlow has developed a technology that can diagnose and enable treatment of the under-perfused coronary microcirculation. We are pleased to have partnered with MCRA to obtain an accelerated pathway to bring the CoFITM system to the US market."  

Michael John, Vice President of Cardiovascular Regulatory Affairs at MCRA, said, "FDA has clearly recognized the need to streamline the regulatory process for potentially disruptive technologies that address an unmet clinical need. CoFITM can diagnose and potentially treat an underappreciated but prevalent and dangerous clinical scenario for which no viable therapeutic options exist.  We were thrilled to assist CorFlow on their Breakthrough Designation Submission for the CoFITM system, and that this novel and differentiated therapy now has an expedited pathway through the regulatory process."

About MCRA, LLC: Founded in 2004, MCRA is a leading Clinical Research Organization (CRO) and advisory firm. MCRA's value contribution rests within in its industry experience at integrating five business value creators: regulatory, reimbursement, clinical research, healthcare compliance, and quality assurance to provide a dynamic, market leading effort from concept to commercialization. MCRA's integrated application of these key value-creating initiatives provides unparalleled expertise for its clients. MCRA has offices in Washington, DC, Manchester, CT, and New York, NY, and serves more than 600 clients globally. Its core focus areas of therapeutic experience include cardiovascular, orthopedics, spine, diagnostic imaging, wound care, dental, general healthcare, digital health, neurology, robotics and in vitro diagnostic (IVD) devices.

Contact
info@mcra.com 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mcra-assists-corflow-in-obtaining-breakthrough-device-designation-300968386.html

SOURCE MCRA, LCC

Chance-Risiko-Profil

Für viele Anleger sieht die ideale Geldanlage so aus: sicher wie eine Anleihe und gleichzeitig renditestark wie eine Aktie. Zertifikate können diee Rolle übernehmen. Wie Sie das Chance-Risiko-Profil Ihres Wertpapierdepots mit Zertifikaten justieren, verrät Ihnen Anlageprofi Anouch Wilhelms von der Commerzbank am Mittwochabend.

Jetzt kostenlos anmelden!
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt mit roten Vorzeichen -- K+S sieht Jahresziele in Gefahr -- Amazon bekommt CL-Rechte -- Deutsche Bank: Gegenwind bei Radikalumbau -- LEONI, JUST EAT, Sanofi, JOST im Fokus

Pfeiffer Vacuum-Aktie auf Talfahrt - Verkaufsempfehlung der DZ Bank. US-Investor KKR nimmt letzte Hürde bei Springer-Einstieg. Brandenburg hofft auf BASF-Batteriefabrik. EZB senkt Kapitalanforderung für Deutsche Bank leicht. Amazon: Druck Trumps schuld an verlorenem Pentagon-Milliardenauftrag. Apple Pay startet bei Sparkassen und weiteren Banken.

Die 5 beliebtesten Top-Rankings

Die Performance der DAX 30-Werte im November 2019.
Welche Aktie macht das Rennen?
Die Performance der Rohstoffe in in KW 49 2019.
Welcher Rohstoff macht das Rennen?
Das hat sich geändert
Diese Aktien hat George Soros im Depot
Das sind die reichsten Länder Welt 2019
Deutschland gerade noch in den Top 20
Hohe Gehälter:
Welche Arbeitgeber am meisten zahlen
mehr Top Rankings

Umfrage

Was wünschen Sie sich von der Großen Koalition?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
Varta AGA0TGJ5
NEL ASAA0B733
EVOTEC SE566480
Apple Inc.865985
BASFBASF11
Amazon906866
Microsoft Corp.870747
CommerzbankCBK100
Ballard Power Inc.A0RENB
Deutsche Telekom AG555750
Infineon AG623100
Allianz840400